Camurus announces expansion of Lilly collaboration

▤ Summary

Camurus announced that Lilly exercised an option to expand their existing collaboration and license agreement. The expansion adds amylin receptor agonists to Lilly’s exclusive global rights to Camurus FluidCrystal technology for long-acting cardiometabolic medicines. The deal now covers up to four Lilly compounds across three drug classes. Camurus receives a $5 million initial payment and remains eligible for substantial development, regulatory, and sales milestones plus royalties. The announcement highlights continued progress in a commercial partnership centered on drug delivery technology.

▦ Linked Companies